This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response

NCT06851169 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib)
DRUG: Cohort 2: Neoadjuvant therapy (benmelstobart only)

Sponsor

Tang-Du Hospital